Responses
Ovarian cancer
2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types
Compose a Response to This Article
Other responses
No responses have been published for this article.